NASDAQ: SANA
Sana Biotechnology is a clinical-stage biotechnology company focused on creating and delivering engineered cells as medicines. The company operates two core technology platforms: a hypoimmune (HIP) cell engineering platform designed to enable allogeneic cell transplantation without immunosuppression, and a fusosome-based in vivo cell engineering platform that delivers genetic material to specific cell types. Its lead programs include SC451, an iPSC-derived pancreatic islet cell therapy for type 1 diabetes; SG293, a CD8-targeted fusosome delivering CD19-directed CAR T cell therapy for non-Hodgkin lymphoma and potentially autoimmune diseases; and SG227, a CD8-targeted fusosome for BCMA-directed CAR T cell therapy in multiple myeloma. The company is pre-revenue and relies on external contract development and manufacturing organizations (CDMOs) for its manufacturing needs. Sana has operations in Seattle, WA, Cambridge, MA, and South San Francisco, CA, and trades on NASDAQ under the ticker SANA. Updated
A beneficial owner stepped up and took a controlling stake in a struggling retailer, while public offerings of stock prompted insider buying at some biotech companies.
Sana Biotechnology is a clinical-stage biotechnology company focused on creating and delivering engineered cells as medicines.
